摘要
Organic sulfone compounds,exhibiting interesting bioactivities,were widely applied in the field of pharmaceutical and medicine.And numerous of sulfuryl group-involved drugs were approved by the Food and Drug Administration(FDA).Odevixibat,maralixibat chloride and belzutifan approved in 2021 could be applied in the treatment of progressive familial intrahepatic cholestasis(PFIC),cholestatic pruritus and clear cell renal cell carcinoma(ccRCC),respectively.In 2022,abrocitinib,pyrukynd and voquezna were approved for the treatment of atopic dermatitis,pyruvate kinase deficiency(PKD)and acid-related disorders,respectively.Defencath for preventing bloodstream infections,sparsentan for treatment of proteinuria related to IgA nephropathy,and xacduro for treatment of hospital-acquired bacterial pneumonia(HABP)were approved in 2023.In this review,the synthesis and therapies of these sulfuryl group-involved drugs approved from 2021 to 2023 are discussed in details.
有机砜类化合物具有独特的生物活性,在制药和医疗等领域有重要的应用价值.许多硫酰基类药物已获得食品药品监督管理局(FDA)认证.2021年,奥维昔巴特、氯马昔巴特以及贝组替凡均获得FDA认证,可分别用于治疗原发性肝内胆汁淤积症(PFIC)、胆汁淤积性瘙痒症和肾透明细胞癌(ccRCC).2022年,阿布罗替尼、pyrukynd和伏诺拉生被FDA批准,分别用于治疗特应性皮炎、多囊肾疾病(PKD)以及酸性相关性疾病.2023年FDA批准了用于预防血流感染的牛磺罗定和肝素、用于治疗IgA肾病相关蛋白尿的司帕生坦,以及用于治疗细菌性肺炎的舒巴坦/杜洛巴坦.本综述详细介绍评述了上述硫酰基类药物的合成和治疗应用.
出处
《有机化学》
SCIE
CAS
CSCD
北大核心
2024年第9期2682-2699,共18页
Chinese Journal of Organic Chemistry
基金
国家自然科学基金(Nos.22277025,21802040)
湖南省湖湘高层次人才聚集工程(创新团队)(No.2021RC5028)
湖南省自然科学基金(Nos.2022JJ80082,2022JJ30240)资助项目.
